

## References

S-221

1. Hematopoietic cell transplantation for idiopathic severe aplastic anemia and Fanconi anemia in children and adolescents. UpToDate, Last update 03/14/2016.
2. Majhail NS, Farnia SH, Carpenter PA, et al. Indications for autologous and allogeneic hematopoietic cell transplantation: Guidelines from the American Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*. 2015;21(11):1863-1869.
3. Abramson DH, Shields CL, Munier FL, et al. Treatment of retinoblastoma in 2015: Agreement and disagreement. *JAMA Ophthalmol*. 2015;133(11):1341-1347.
4. Malogolowkin MH, Hemmer MT, Le-Rademacher J, et al. Outcomes following autologous hematopoietic stem cell transplant for patients with relapsed Wilms' tumor: A CIBMTR retrospective analysis. *Bone Marrow Transplant*. 2017:1-7.
5. Khandelwal P, Millard HR, Thiel E, et al. Hematopoietic stem cell transplantation activity in pediatric cancer between 2008 and 2014 in the united states: A center for international blood and marrow transplant research report. *Biol Blood Marrow Transplant*. 2017;23(8):1342-1349.
6. Armstrong AE, Danner-Koptik K, Golden S, et al. Late effects in pediatric high-risk neuroblastoma survivors after intensive induction chemotherapy followed by myeloblastic consolidation chemotherapy and triple autologous stem cell transplants. *J Pediatr Hematol Oncol*. 2017:1-5.
7. Portwine C, Rae C, Davis J, Teira P, Schechter T, et al. Health-Related Quality of Life in Survivors of High-Risk Neuroblastoma After Stem Cell Transplant: A National Population-Based Perspective. *Pediatr Blood Cancer*. 2016;63:1615–1621.
8. National Cancer Institute (NCI). Physician Data Query (PDQ): Neuroblastoma treatment. 2020. Accessed September 14, 2020.
9. Atas E, Kutluk MT, Akyuz C. Clinical Features and Treatment Results of Children with High-Risk Neuroblastoma Undergone to Autologous Stem Cell Transplantation. *Int J Hemato and Oncol*. 2018;3(18);187-196.

10. Stewart E, Federico S, Karlstrom A, et al. The Childhood Solid Tumor Network: A new resource for the developmental biology and oncology research communities. *Dev Biol.* 2016;411(2):287-293.
11. National Cancer Institute (NCI). Physician Data Query (PDQ): Childhood rhabdomyosarcoma treatment. 2020. Accessed September 14, 2020.
12. National Cancer Institute (NCI). Physician Data Query (PDQ): Retinoblastoma treatment: health professional version. 2019. Accessed September 14, 2020.
13. Yalcin B, Kremer LC, van Dalen EC. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma. *Cochrane Database Syst Rev.* 2015(10):CD006301.
14. Proust-Houdemont S, Pasqualini C, Blanchard P, et al. Busulfan-melphalan in high-risk neuroblastoma: the 30-year experience of a single institution. *Bone Marrow Transplant.* 2016;51(8):1076-1081.
15. Pasqualini C, Dufour C, Goma G, et al. Tandem high-dose chemotherapy with thiotepa and busulfan-melphalan and autologous stem cell transplantation in very high-risk neuroblastoma patients. *Bone Marrow Transplant.* 2016;51(2):227-231.
16. Loschi S, Dufour C, Oberlin O, et al. Tandem high-dose chemotherapy strategy as first-line treatment of primary disseminated multifocal Ewing sarcomas in children, adolescents and young adults. *Bone Marrow Transplant.* 2015;50(8):1083-1088.
17. Venkatramani R, Murray J, Helman L, et al. Risk-based therapy for localized osteosarcoma. *Pediatr Blood Cancer.* 2016;63(3):412-417.
18. Hong CR, Kang HJ, Kim MS, et al. High-dose chemotherapy and autologous stem cell transplantation with melphalan, etoposide and carboplatin for high-risk osteosarcoma. *Bone Marrow Transplant.* 2015;50(10):1375-1378.
19. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Bone Cancer. Version 1.2020. Accessed September 14, 2020.
20. Portwine C, Rae C, Davis J, et al. Health-related quality of life in survivors of high-risk neuroblastoma after stem cell transplant: A national population-based perspective. *Pediatr Blood Cancer.* 2016;63(9):1615-1621.

21. Park JR, Kreissman SG, London WB, et al. Effect of tandem autologous stem cell transplant vs single transplant on event-free survival in patients with high-risk neuroblastoma: A randomized clinical trial. *JAMA*. 2019;322(8):746-755.
22. Tenneti P, Zahid U, Iftikhar A, et al. Role of high-dose chemotherapy and autologous hematopoietic cell transplantation for children and young adults with relapsed ewing's sarcoma: A systematic review. *Sarcoma*. 2018:1-12.